Reviewing vTv Therapeutics Inc. (VTVT)’s and Asterias Biotherapeutics Inc. (:)’s results – MS Wkly

vTv Therapeutics Inc. (NASDAQ:VTVT) and Asterias Biotherapeutics Inc. (:) are two firms in the Biotechnology that compete against each other. Below is a comparison of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation.

Valuation and Earnings

We can see in table 1 the earnings per share, top-line revenue and valuation of vTv Therapeutics Inc. and Asterias Biotherapeutics Inc.

Profitability

Table 2 provides the return on equity, net margins and return on assets of the two firms.

Analyst Ratings

In next table is delivered vTv Therapeutics Inc. and Asterias Biotherapeutics Inc.s ratings and recommendations.

vTv Therapeutics Inc. has a 224.68% upside potential and a consensus target price of $5.

Insider & Institutional Ownership

The shares of both vTv Therapeutics Inc. and Asterias Biotherapeutics Inc. are owned by institutional investors at 7.3% and 13.75% respectively. 69.32% are vTv Therapeutics Inc.s share owned by insiders. Insiders Competitively, owned 40.53% of Asterias Biotherapeutics Inc. shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Summary

vTv Therapeutics Inc. beats Asterias Biotherapeutics Inc. on 6 of the 9 factors.

vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates worldwide. The companys drug candidate for the treatment of Alzheimers disease comprise azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase III clinical trials. Its type 2 diabetes drug candidates include TTP399, an orally administered, liver-selective glucokinase activator that has been completed Phase IIb clinical trials; and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor, which is in Phase II clinical trials. The company has a license and research agreement with Calithera Biosciences, Inc. to develop and commercialize its hexokinase II inhibitors for therapeutics, prophylactic, preventative, or diagnostic use. vTv Therapeutics Inc. was founded in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. operates as a subsidiary of M&F TTP Holdings Two LLC.

Asterias Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapies in the fields of cell therapy and regenerative medicine. The company develops therapeutic products in the areas of neurology and oncology. Its clinical stage programs include AST-OPC1, a therapy derived from pluripotent stem cells that has completed a Phase I clinical trial for the treatment of thoracic spinal cord injuries; and that is in Phase I/IIa clinical trial for treating cervical spinal cord injuries, as well as for the treatment of multiple sclerosis and white matter stroke. The company also develops immunotherapeutic programs, such as AST-VAC1, an autologous product candidate that has completed a Phase II clinical trial for the treatment of acute myelogenous leukemia; and AST-VAC2, which is in a Phase I/IIa clinical trial, an allogeneic and cancer vaccine candidate designed to stimulate patient immune responses to telomerase. The company was formerly known as BioTime Acquisition Corporation and changed its name to Asterias Biotherapeutics, Inc. in March 2013. Asterias Biotherapeutics, Inc. was founded in 2012 and is headquartered in Fremont, California. Asterias Biotherapeutics, Inc. is a subsidiary of BioTime, Inc.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

See more here:
Reviewing vTv Therapeutics Inc. (VTVT)'s and Asterias Biotherapeutics Inc. (:)'s results - MS Wkly